2024.11.20 (수)

  • 흐림동두천 1.3℃
  • 구름많음강릉 8.0℃
  • 흐림서울 3.8℃
  • 구름많음대전 1.6℃
  • 구름조금대구 3.5℃
  • 구름조금울산 6.5℃
  • 구름많음광주 6.3℃
  • 맑음부산 10.0℃
  • 구름조금고창 3.0℃
  • 제주 11.7℃
  • 구름많음강화 2.4℃
  • 구름많음보은 -0.7℃
  • 구름많음금산 -0.3℃
  • 흐림강진군 9.3℃
  • 구름조금경주시 3.3℃
  • 흐림거제 8.2℃
기상청 제공

경제

CHMP Recommends EU Approval of VIZAMYL™ (Flutemetamol F18 Injection) for PET Imaging of Beta Amyloid Plaque

[By NBC-1TV H. J Yook]GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the granting of a marketing authorisation for VIZAMYL™ (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL™ is for diagnostic use only and should be used in conjunction with a clinical evaluation.

“The CHMP positive recommendation further strengthens GE Healthcare’s longstanding commitment to the early and accurate detection of AD pathology and to improving quality of life for patients and their caregivers,” said Kieran Murphy, President and CEO, Life Sciences, GE Healthcare. “When approved in the European Union, VIZAMYL will be an important tool to support assessments of patients with cognitive disorders, including AD.”

PET imaging with VIZAMYL detects the accumulation of beta amyloid in the brain, one of the pathological in-vivo markers of AD, and allows for visual interpretation of colour images. While VIZAMYL does not establish a diagnosis for AD or other cognitive disorders, it is a useful tool in conjunction with a clinical evaluation, and may have the potential to lead to earlier diagnosis and intervention in the future.

“AD is a major unmet medical need and the lack of diagnostic tools increases the potential for diagnostic uncertainty and the risk of mismanagement,” said Professor Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center, Amsterdam. “Once approved, VIZAMYL may help physicians to assess specific patients with suspected Alzheimer’s disease. This may help physicians determine appropriate treatment options, support patients and caregivers in planning for the future, and support clinical researchers in identifying patients for clinical trials.”



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너